These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18824122)

  • 1. CB(1) receptor antagonism: biological basis for metabolic effects.
    Di Marzo V
    Drug Discov Today; 2008 Dec; 13(23-24):1026-41. PubMed ID: 18824122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
    Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
    J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.
    Mach F; Montecucco F; Steffens S
    Pharmacol Rep; 2009; 61(1):13-21. PubMed ID: 19307689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
    Silvestri C; Di Marzo V
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
    Doggrell SA
    Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
    [No Abstract]   [Full Text] [Related]  

  • 6. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
    Dibble CT; Gelfand EV; Cannon CP
    Curr Atheroscler Rep; 2007 Nov; 9(5):359-66. PubMed ID: 18001618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
    Jbilo O; Ravinet-Trillou C; Arnone M; Buisson I; Bribes E; Péleraux A; Pénarier G; Soubrié P; Le Fur G; Galiègue S; Casellas P
    FASEB J; 2005 Sep; 19(11):1567-9. PubMed ID: 16009704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.
    Bronander KA; Bloch MJ
    Vasc Health Risk Manag; 2007; 3(2):181-90. PubMed ID: 17580728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.
    Lafontan M; Piazza PV; Girard J
    Diabetes Metab; 2007 Apr; 33(2):85-95. PubMed ID: 17418607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rimonabant--a selective CB1 antagonist.
    Boyd ST; Fremming BA
    Ann Pharmacother; 2005 Apr; 39(4):684-90. PubMed ID: 15755787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice.
    Lazzari P; Sanna A; Mastinu A; Cabasino S; Manca I; Pani L
    Behav Brain Res; 2011 Mar; 217(2):432-8. PubMed ID: 21074566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocannabinoid control of food intake and energy balance.
    Di Marzo V; Matias I
    Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity.
    Duffy D; Rader D
    Trends Cardiovasc Med; 2007 Feb; 17(2):35-43. PubMed ID: 17292044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
    Jourdan T; Demizieux L; Gresti J; Djaouti L; Gaba L; Vergès B; Degrace P
    Hepatology; 2012 Mar; 55(3):790-9. PubMed ID: 21987372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Boekholdt SM; Jukema JW; Peters RJ
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.
    Gelfand EV; Cannon CP
    J Am Coll Cardiol; 2006 May; 47(10):1919-26. PubMed ID: 16697306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rimonabant: new data and emerging experience.
    Wright SM; Dikkers C; Aronne LJ
    Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
    Cota D; Sandoval DA; Olivieri M; Prodi E; D'Alessio DA; Woods SC; Seeley RJ; Obici S
    Obesity (Silver Spring); 2009 Aug; 17(8):1641-5. PubMed ID: 19325539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.